Compare Arista Networks Inc (ANET) vs Regeneron Pharmaceuticals Inc (REGN) Price & Performance

Arista Networks (ANET) trades at $186.96, up 1.23% with strong technical momentum as price approaches resistance at $189. The company demonstrates robust fundamentals with 2025 revenue of $9.01B and net income of $3.51B (38.32% margin), though valuation metrics remain elevated with P/E of 64.25. Recent earnings beats and AI infrastructure tailwinds support positive sentiment.

Arista presents growth potential from AI networking demand with 75% analyst buy ratings and $192.82 consensus target, but faces risks from high valuation multiples and competitive pressures. The stock's technical setup suggests near-term resistance testing with support at $180, while fundamental strength supports long-term growth outlook.

Regeneron (REGN) trades at $664.52, down 0.54% on the day, with a bullish technical signal from moving averages but overbought RSI readings. The company maintains strong fundamentals with a P/E of 16.22, net income margin of 29.65%, and consistent earnings beats. Recent FDA acceptance for cemdisiran review and inclusion in a manufacturing facility pilot program highlight positive developments. Cash flow improved in 2025 with net cash flow of $634.70 million.

Outlook remains positive with a consensus price target of $764.50, implying 15% upside, supported by 69% analyst buy ratings. Risks include regulatory hurdles, competitive pressures, and dependence on key drug performance. The stock presents a compelling opportunity for growth investors given its valuation and pipeline progress, though near-term volatility may persist around earnings.